Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15117036 | 0.84 | AR (0.57) | ARENPP1KDM4EALDH1A1 | |
| SCHEMBL2468096 | 0.82 | AR (0.55) | ARENPP1KDM4EALDH1A1GAA | |
| SCHEMBL4232664 | 0.82 | AR (0.55) | ARENPP1KDM4EALDH1A1PDPK1 | |
| SCHEMBL13280835 | 0.82 | LMNA (0.53) | ARENPP1KDM4EGAAPDPK1 | |
| SCHEMBL12955359 | 0.81 | AR (1.00) | ARENPP1 | |
| SCHEMBL4488375 | 0.80 | HSPA5 (0.48) | ARKDM4EALDH1A1GAAPDPK1 | |
| SCHEMBL2731246 | 0.78 | AR (0.50) | ARKDM4EALDH1A1HPGD | |
| SCHEMBL3583918 | 0.78 | AR (0.61) | ARENPP1KDM4EALDH1A1 | |
| SCHEMBL2468319 | 0.77 | MAPT (0.54) | ARENPP1HPGDCNR1CNR2 | |
| SCHEMBL693552 | 0.77 | PARP1 (0.52) | ARENPP1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-8309551-B2 | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309551-B2 | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-8309551-B2 | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20100029653-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029653-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029653-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-2066666-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031513-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031513-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | AR 4285/4885ENPP1 2023/4885CTNNB1 2601/4885 |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | AR 4285/4885ENPP1 2023/4885CTNNB1 2601/4885 |
| US-20100029653-A1 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | PDE3A, PDE2A, PDE3B | AR 4553/4885ENPP1 216/4885CTNNB1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.